The drug maker said that the company has received the establishment inspection report (EIR) from the United States Food & Drug Administration (USFDA) for its manufacturing facility in Visakhapatnam, Andhra Pradesh.
In October last year, the USFDA had conducted a pre-approval inspection (PAI) at the company's manufacturing facility located at Unit-5, Parawada, Visakhapatnam, Andhra Pradesh. The inspection was done between 24th October 2022 and 28th October 2022.
At the end of the inspection, the pharmaceutical company was issued a Form 483 with one observation by the US drug regulator. The observation is procedural in nature, the pharma company stated and added that it would address the observation within stipulated timelines.
Laurus Labs is a fully integrated pharmaceutical and biotechnology company, with a leadership position in generic Active Pharmaceutical Ingredients (APIs) and a major focus on anti-retroviral, Hepatitis C, and oncology drugs.
The pharmaceutical company posted a 15% rise in consolidated net profit to Rs 233 crore on a 31% increase in revenue from operations to Rs 1,230 crore in Q2 FY23 over Q2 FY21.
The scrip shed 0.26% to currently trade at Rs 350.60 on the BSE.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve hit your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Quarterly Starter
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Access to Exclusive Premium Stories Online
Over 30 behind the paywall stories daily, handpicked by our editors for subscribers
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app